Hyperlipidemia and ASCVD Risk Reduction Pharmacy

How To Take A quiz?

Fill out all required information.
Carefully read the question.
Then choose the answer and click on it.
Correct/Incorrect response will be displayed.
Use "Next" button to go to the next question.
Score will be shown at the conclusion of the quiz.
Received Passing score - Great ! close the browser window
Received Failed score - Retake quiz until you pass

Ready? Let's click on "Start Quiz" button and get started !

Please enter Full Legal Name (First and Last Name) & Required Information to be printed on the certificate. CPE Monitor Reporting is done electronically on the same day of completion (must provide all required information matching with your NABP e-profile).

1 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 1:

What is the primary lipid target in ASCVD risk reduction?

A) HDL-C

B) Triglycerides

C) LDL-C

D) Total cholesterol

2 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 2:

Which of the following is a high-intensity statin?

A) Simvastatin 20 mg

B) Atorvastatin 40 mg

C) Pravastatin 20 mg

D) Rosuvastatin 5 mg

3 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 3:

What tool is commonly used to estimate 10-year ASCVD risk?

A) Framingham Score

B) CAC score

C) Pooled Cohort Equation

D) QRISK

4 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 4:

According to ACC/AHA guidelines, what LDL-C goal is recommended for patients with very high ASCVD risk?

A) <130 mg/dL

B) <100 mg/dL

C) <70 mg/dL

D) <55 mg/dL

5 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 5:

Which of the following is NOT a common adverse effect of statins?

A) Hypoglycemia

B) Myopathy

C) Elevated liver enzymes

D) Headache

6 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 6:

What nonstatin medication works by inhibiting cholesterol absorption in the intestine?

A) PCSK9 inhibitor

B) Bempedoic acid

C) Ezetimibe

D) Niacin

7 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 7:

Which lifestyle modification has the greatest potential to raise HDL-C?

A) Smoking cessation

B) Reducing saturated fats

C) Increasing soluble fiber

D) Weight gain

8 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 8:

What is a common triglyceride level above which the risk of pancreatitis increases significantly?

A) >150 mg/dL

B) >2000 mg/dL

C) >500 mg/dL

D) >1000 mg/dL

9 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 9:

What is the main benefit of Coronary Artery Calcium (CAC) scoring?

A) To estimate blood pressure

B) To guide statin decision-making in borderline risk

C) To detect diabetes

D) To assess renal function

10 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 10:

Which guideline primarily recommends targeting LDL-C <55 mg/dL in very high-risk patients?

A) ACC/AHA

B) ADA

C) AACE

D) WHO

11 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 11:

Which of the following is true about icosapent ethyl?

A) Raises LDL-C

B) Should be used in all patients with high HDL

C) Is used for TG >500 mg/dL

D) Lowers CV risk in statin-treated patients with elevated TG

12 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 12:

Which statin is considered hydrophilic and may be preferred in statin intolerance?

A) Pravastatin

B) Atorvastatin

C) Simvastatin

D) Lovastatin

13 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 13:

According to ADA guidelines, what is the LDL-C goal in patients with diabetes and high CV risk?

A) <130 mg/dL

B) <100 mg/dL

C) <70 mg/dL

D) <55 mg/dL

14 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 14:

A patient with LDL-C ≥190 mg/dL is started on a high-intensity statin. After 6 weeks, LDL-C remains at 120 mg/dL. What is the next best step?

A) Increase statin dose

B) Add ezetimibe

C) Stop statin

D) No changes needed

15 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 15:

Which of the following is a contraindication to statin use?

A) Pregnancy

B) Diabetes

C) CKD

D) Mild myalgia

16 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 16:

What is the mechanism of action of PCSK9 inhibitors?

A) Inhibit cholesterol synthesis

B) Increase LDL receptor recycling

C) Block triglyceride absorption

D) Decrease bile acid production

17 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 17:

What is the key role of clinicians in lipid management?

A) Interpreting echocardiograms

B) Prescribing insulin

C) Counseling on statin adherence and lifestyle changes

D) Performing cardiac catheterizations

18 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 18:

Which of the following patients would benefit most from a CAC score?

A) 75-year-old with prior MI

B) 22-year-old with familial hypercholesterolemia

C) 58-year-old with borderline ASCVD risk, unsure about statins

D) Patient already on PCSK9 inhibitor

19 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 19:

Which dietary component is most associated with lowering LDL-C?

A) Trans fats

B) Soluble fiber

C) Added sugars

D) Red meat

20 / 20

Hyperlipidemia and ASCVD Risk Reduction

Question 20:

What effect does bempedoic acid have on LDL-C?

A) Increases it

B) No effect

C) Mild decrease

D) Moderate reduction (~15–20%)

Your score is

Our Course Categories

Unlimited CEUs

Infection Control

Dental

Nursing

Pharmacy

Physical Therapy

Occupational Therapy

Massage Therapy

Rehab CE (🎥+PDF)

SLP & Audiology

Pharmacology CE

LCSWs/MFTs/LMHCs

Compliance

Tattoo/Body Art BBP

HIPAA Training

Biologix Solutions LLC